Shots:

• Recursion to receive $30M as up front- $50M as equity investment- ~$100M/ program as development and commercial milestones along with royalties on sales. The companies will work on more than ten programs
• Bayer will get an exclusive option to license novel therapies derived from the research activities
• The collaboration will deploy Recursion’s AI-guided drug discovery platform and Bayer’s small molecule compound library and expertise to discover and develop new treatments for fibrotic diseases of the lung- kidney- heart

­ Ref: PRNewswire | Image: Michigan Health Lab